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Background: Cost-effectiveness studies of lifestyle interventions in people at risk for lifestyle-related diseases,
addressing ‘real-world’ implementation, are needed. This study examines the cost-effectiveness of a primary care
intervention from a societal perspective, compared with provision of health brochures, alongside a randomized
controlled trial.
Methods: Adults aged 30-50 years, at risk of type 2 diabetes (T2DM) and/or cardiovascular disease (CVD), were
recruited from twelve general practices in The Netherlands. They were randomized to the intervention (n = 314) or
control group (n = 308). The intervention consisted of up to six face-to-face counseling sessions with a trained
practice nurse, followed by three-monthly sessions by phone. Costs were collected using three-monthly
retrospective questionnaires. Quality of life was measured with the EuroQol-5D-3L, at baseline, 6, 12 and 24 months.
Nine-year risk of developing T2DM and ten-year risk of CVD mortality were estimated using the ARIC and SCORE
formulae, respectively, based on measurements at baseline and 24 months while applying a fixed age of 60 years at
both time points.
Results: Small, statistically non-significant differences in effects were found between the intervention and control
group with regard to risk scores and Quality Adjusted Life Years (QALYs) gained. The mean difference in costs
between the intervention and control group was €-866 (95% confidence interval -2372; 370). The probability that
the intervention was cost-effective varied from 93% at €8000/QALY to 88% at €80,000/QALY.
Conclusion: A primary care lifestyle intervention aimed at adults at increased risk of T2DM and/or CVD could result
in cost savings over a two-year period. However, due to methodological uncertainty no advice can be given
regarding the implementation of the intervention in Dutch general practices.
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Worldwide an increased prevalence of type 2 diabetes
(T2DM) has been noted over the last decades [1]. A fur-
ther rise is expected, due to an aging population and the
high prevalence of obesity. The expected increase is not
only a medical, but also a socioeconomic problem. In
most countries health care costs are rapidly rising, and
the obesity epidemic plays an important role in this
process [2]. Several studies have shown that the risk of
developing T2DM and associated cardiovascular diseases
(CVDs) reduces with weight loss and improved lifestyle
behaviors [3]. A recent review found evidence for the
cost-effectiveness of diabetes prevention interventions
[4]. Nevertheless, as these interventions have been stud-
ied under strictly controlled conditions, there remains
a need for cost-effectiveness studies of interventions
addressing ‘real-world’ settings. Information about the
tradeoff between costs and benefits of these interven-
tions will help policy makers to decide whether it is effi-
cient to implement and reimburse them.
In the Netherlands, a theory-based primary care inter-
vention aimed at reducing the risk of T2DM and CVD
was developed and tested in general practices using a
randomized controlled trial (RCT) design [5]. The pur-
pose of the current study is to assess the cost-utility and
cost-effectiveness of the intervention in reducing the risk
for developing T2DM and CVD, compared with the
provision of health brochures. The primary outcome of
the study is the number of Quality Adjusted Life Years
(QALYs) gained. Secondary outcomes are changes in es-
timated risk of developing T2DM in the following 9 years
and of CVD mortality in the following 10 years. These
outcomes are assessed within the two year trial period.
Methods
Design of the study
An economic evaluation was conducted alongside a
RCT, the Hoorn Prevention Study, carried out in the
Netherlands from 2008 to 2010. The economic evalu-
ation was performed from a societal perspective. Details
of the study design, the recruitment results and the im-
plementation of the intervention have been published
elsewhere [5,6]. The study design and informed consent
procedure were approved by the Medical Ethics Com-
mittee of the VU University Medical Center and all par-
ticipants provided written informed consent.
Study population and setting
The study population consisted of men and women liv-
ing in several municipalities in the semi-rural region
around the city of Hoorn in the Netherlands. The region
has over 200,000 inhabitants. Twelve general practitioners
provided the addresses of 8193 of their patients, aged 30-
50 without known diabetes or CVD, based on patientrecords. These persons were asked by mail to measure
their waist circumference with a paper tape measure pro-
vided to them. Waist circumference reflects the magnitude
of abdominal adipose tissue deposits as well as total fat
mass [7]. It is considered to be a good measure with which
to identify persons with an increased risk of developing
T2DM and CVD [8]. Of the 3587 responders, 921 had an
increased waist-circumference (≥101 cm for men and
≥87 cm for women). These 921 persons were invited for
baseline measurements, of which 772 attended. At base-
line, the at the age of 60 years anticipated 9-year risk of
developing T2DM and the 10-year risk of CVD mortality
were estimated, assuming all other risk factors would re-
main unchanged [5]. We did this by setting the age of all
participants to 60 years in our risk score calculations. This
projection was done to address the problem of a current
low absolute risk due to a relative young age which, if no
improvements occur, would develop to a high risk at age
60 [9]. Responders with a minimum estimated risk of 10%
on one or both risk scores were eligible. Reasons for exclu-
sion were pregnancy, unable to communicate adequately
in the Dutch language or being diagnosed with T2DM or
CVD. A total of 150 respondents were excluded, because
of low risk (n = 140) or T2DM diagnosis (n = 10). A to-
tal of 622 participants were randomly assigned to either
the intervention group (n = 314) or the control group
(n = 308; Figure 1). Random allocation was done in blocks
of 10 to keep the sizes of treatment groups similar, using a
computerized random number generator. If there was
more than one participant from the same family, the con-
secutive members of that family were allocated to the
same group to avoid contamination. Randomization was
performed by an independent administrative assistant
from the Diabetes Research Center, who was not involved
in the intervention, measurements or analyses.Intervention and control
Both groups received care as usual, e.g. prescription
of medication in the case of severe hypertension.
Additionally, an intervention based on cognitive behav-
ioral principles was offered to the intervention group. The
intervention was aimed at improving physical activity, diet
or smoking behavior, as chosen by the participants. It
consisted of up to six monthly individual 30-minute face-
to-face counseling sessions, followed by three-monthly 15-
minute sessions by phone. Counseling was done by eight
practice nurses, who received 18 hours of training prior to
the intervention. Feedback on the quality of counseling
was provided to the practice nurses halfway through the
sessions and consisted of one hour individual coaching.
Also, a peer supervision meeting was arranged. A full de-
scription of the intervention and its underlying principles
has been published elsewhere [5].
Figure 1 Participant flow. T2DM, Type 2 Diabetes Mellitus; CVD, Cardiovascular Disease, QALYs, Quality Adjusted Life Years. T2DM risk: the 9-year
risk of developing T2DM; CVD risk: the 10-year risk of CVD mortality.
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taining health guidelines regarding physical activity and a
healthy diet, obtained from the Dutch Heart Foundation.
Smokers received an additional brochure on how to stop
smoking from the Dutch expertise center for tobacco dis-
couragement policies (STIVORO). An independent admin-
istrative assistant sent the brochures to the participants.
Study measures
Clinical outcome measures
For the cost-utility analysis, the EuroQol-5D with three
levels for each of the five health dimensions (EQ-5D-3L)
was used to assess quality of life at baseline, and at 6, 12
and 24 month follow-up [10]. Health utilities wereestimated with the Dutch tariff [11]. QALYs were calcu-
lated by multiplying the utilities with the amount of time
a participant spent in a particular health state. Transi-
tions between health states were linearly interpolated.
Outcome measures of the cost-effectiveness analyses
were the estimated risk of developing T2DM and the es-
timated risk of CVD mortality. The 9-year risk of de-
veloping T2DM was estimated with the risk formula
derived from the Atherosclerosis Risk In Communities
(ARIC) Study, based on ethnicity, parental history of dia-
betes, systolic blood pressure, waist circumference, and
height [12]. This formula was selected because of its po-
tential applicability in primary care, since it includes
only non-invasive methods to assess participants’ T2DM
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with the formula developed by the Systematic COronary
Risk Evaluation (SCORE) project [9] which includes sex,
smoking status, total cholesterol, and systolic blood pres-
sure. The application of the SCORE formula was consid-
ered to be the most useful for the calculation of CVD mor-
tality risk. Former comparative analyses of the SCORE, the
Framingham and the UKPDS formulae demonstrated that
the Framingham function may overestimate an individual’s
absolute chronic heart disease risk, and the UKPDS for-
mula was not chosen based on its specific inclusion of
T2DM as variable [13]. Baseline risks and follow-up risks
were estimated while standardizing the age of each partici-
pant at 60 years. The formulas and the estimated risks are
further explained in Additional file 1. Data was collected
by means of physical measurements and questionnaires. A
detailed description of the data collection has previously
been published [5].
Cost measures
Information on health care utilization, medication costs,
participant costs and productivity loss was obtained
through eight retrospective three-month questionnaires
provided to the participants between baseline and
24-month follow-up.
Health care utilization consisted of general practitio-
ner care, allied health care, medical specialist care and
hospitalization [14]. Participants’ costs concerned comple-
mentary care, over-the-counter (OTC) medication, and
costs associated with improving physical activity, such as
sports club memberships and sports equipment. Health
care utilization and complementary care were valued with
Dutch standard costs. When these were not available,
prices reported by professional associations were used. The
costs of prescribed medication were calculated using prices
charged by the Royal Dutch Society for Pharmacy [15].
Costs of OTC medication and sports were reported by the
participants. Costs of productivity losses based on self-
reported sick leave from work were estimated with the fric-
tion cost approach (friction period 154 calendar days and
an elasticity of 0.8), using the mean income of the Dutch
population according to age and gender [14]. Cost categor-
ies and prices used in the economic evaluation can be
found in Additional file 2. Prices were adjusted to the year
2008 (the year of the first measurement) using consumer
price indices [16]. In the base case analysis no discounting
was done for the costs in the second year. The effect of
discounting was however explored in a sensitivity analysis.
Intervention costs
Bottom-up micro-costing was used to estimate interven-
tion costs. These consisted of a sum of fixed costs and
variable costs. The fixed costs covered costs of the devel-
opment and printing of materials, training and supervisionof the practice nurses, and of costs for selecting and invit-
ing the participants. Of the 207,000 inhabitants in the re-
gion, around 27% is between 30 and 50 years old. Of these
56,000 people, about one-fifth is expected to be eligible
and willing to participate. Development costs were there-
fore spread over 10,000 patients. Total fixed costs per par-
ticipant were €15. Variable costs per participant consisted
of counseling costs. These were calculated based on the
number of face-to-face contacts and telephone contacts
that took place as reported by the practice nurse. The cost




Analyses were based on group allocation, regardless of ac-
tual intervention received or of adherence to the interven-
tion (i.e. intention-to-treat). In the base case analysis it
was assumed that when data on follow-up telephone ses-
sions were missing, no sessions had taken place and the
missing data were imputed with zero. The reason for
doing so was that many practice nurses failed to report
the number of follow-up phone contacts they had with a
particular participant. It seems fair to assume that this was
because none took place. Missing number of face-to-face
contacts, health care costs, participant costs, sick leave
days and clinical outcomes were imputed using multiple
imputation techniques [17]. The imputation model in-
cluded age, sex, educational level, smoking status, living
alone yes/no, baseline outcome values, available midpoint
(6 and 12 months) and follow-up outcome values, and
available number of face-to-face and phone sessions,
health care costs, participant costs and sick leave days at
each measurement. Imputations were done separately for
the intervention and control group. Five different data sets
were created in SPSS (version 17.0.2, Chicago, Ill) using
Fully Conditional Specification and Predictive Mean
Matching procedures, assuming that data were missing at
random [18]. These data sets were analyzed as specified
below. The estimates were pooled with methods described
by Rubin [19]. This method does not allow for an estima-
tion of standard deviations, so the standard error of the
mean (SEM) is presented to describe variability.
Base case analysis
Costs and outcomes were estimated separately. Linear
regression analysis (ordinary least squares) was used to
compare outcomes between the intervention and control
groups. Follow-up outcomes were adjusted for baseline
values [20]. To compare costs between groups, confi-
dence intervals around the mean differences in costs
were estimated using the bias-corrected and accelerated
bootstrap method with 5000 replications. Incremental cost-
effectiveness ratios (ICERs) were estimated by dividing the
Table 1 Baseline characteristics of all randomized
participants
Control group Intervention group
n = 308 n = 314
Female [n (%)] 185 (60.1) 178 (56.7)
Age [mean (SD), (years)] 43.4 (5.5) 43.6 (5.1)
Level of education [n(%)]a
≤ Primary education 103 (33.6) 101 (32.5)
Secondary education 145 (47.1) 141 (44.9)
College, university 59 (19.2) 69 (22.0)
Paid job [n (%) yes]b 269 (87.9) 262 (85.6)
Smoking [n (%) yes]a 54 (17.5) 74 (23.9)
T2DM risk [mean (SD)], % 18.8 (8.5) 19.0 (7.8)
CVD risk [mean (SD)]e, % 3.8 (2.9) 4.0 (3.0)
Health utility [mean (SD)]f 0.90 (0.13) 0.88 (0.16)
T2DM, Type 2 Diabetes Mellitus; CVD, Cardiovascular Disease. a n = 617;
b n = 612; c The at the age of 60 years anticipated of developing T2DM in the
following 9 years; d The at the age of 60 years anticipated risk of CVD
mortality in the following ten years; e n = 619; f n = 612,
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ment groups by the regression coefficient for treatment ef-
fect at 24 months. To graphically present uncertainty
around the ratios, bias-corrected percentile bootstrapped
cost-effect pairs (5000 replications) were plotted in cost-
effectiveness planes (CE-planes) [21]. The uncertainty of
cost-effectiveness was presented in cost-effectiveness ac-
ceptability curves (CEACs) [22]. Analyses were performed
with R version 2.10.1 [23]. Participants who developed
CVD or T2DM during the study (n = 9) or became preg-
nant (n = 7), and participants who had died (n = 1) were ex-
cluded from all analyses.
Sensitivity analyses
Sensitivity analyses were conducted to test the robustness
of the results. In the first sensitivity analysis the costs for
the second year were discounted with 4% and QALYs
achieved in this year were discounted with 1.5%, in line
with Dutch guidelines [24]. In the second sensitivity ana-
lysis the productivity losses were valued with the human
capital method. In the third sensitivity analysis the costs
for sports were excluded. In the fourth sensitivity analysis,
missing data for follow-up phone calls (which in the base
case analysis were assumed to be zero) were multiply im-
puted. For the fifth sensitivity analysis, 50 multiply im-
puted files were created, according to the rule of thumb
that the number of imputed files should at least equal the
fraction of incomplete cases [25]. The sixth sensitivity ana-
lysis was restricted to participants with complete cost and
effect data, i.e., complete case analysis (CCA). In the final
sensitivity analysis, cost-effectiveness was assessed from
the healthcare perspective.
Results
Participant flow and baseline characteristics
The participant flow is presented in Figure 1. On aver-
age, 64% of the cost questionnaires were fully completed
and returned. Data on the number of face-to-face and
phone counseling sessions, necessary to calculate the
intervention costs, were complete for, respectively, 291/
314 (93%) and 177/314 (56%) participants. As a conse-
quence, 36 to 44% of the cost data were imputed, as was
22 to 26% of the outcome data.
Baseline characteristics are given in Table 1.
Intervention compliance
The mean number of face-to-face counseling sessions
after multiple imputation was 2.4 (SEM 0.08). The mean
number of follow-up phone sessions was 2.3 (SEM 0.2).
The findings of our process evaluation indicate that prac-
tice nurses adhered to the intervention protocol and were
reasonably competent and confident in the provision of
the intervention [6].Clinical outcomes
QALYs achieved during the two-year period were 1.81
(SEM 0.01) in the control group, and 1.80 (SEM 0.02) in
the intervention group. After adjustment for baseline
utilities, the intervention group gained a statistically
nonsignificant 0.02 (95% CI -0.02 to 0.05) more QALYs
than the control group.
Both groups improved their risk of T2DM and CVD.
Respectively, these reduced to 17.9% (SEM 0.5) and 3.6%
(SEM 0.2) in the control group, and 18.5% (SEM 0.5) and
3.7% (SEM 0.2) in the intervention group. Only minimal
and statistically non-significant differences were found be-
tween the groups. The intervention group experienced a
relative increase in T2DM risk of 0.6% (95% CI -0.1 to 1.3)
and a decrease in CVD risk of 0.1% (95% CI -0.4 to 0.2),
compared with the control group.
Costs
The mean costs and cost differences in each cost cat-
egory are presented in Table 2. Intervention costs were
€98 (SEM 2.4) per participant. The majority of partici-
pant costs consisted of costs for sports and sports equip-
ment (88%). Indirect costs of productivity losses ranged
from €0 to €71,695 in the control group and €0 to
€45,195 in the intervention group. Statistically significant
differences in costs between the groups were not seen.
The direction of the cost-differences in each category
was consistently in favor of the intervention group. The
overall cost-difference was €-866 (95% CI -2392 to 370).
Cost-utility
The incremental cost-effectiveness ratio of €-50,273
per QALY gained was reflective of a small gain in
QALYs (0.02) in the intervention group, at a reduction
Table 2 Pooled costs and cost differences in Eurosa between baseline and two year follow-up, after multiple
imputation
Control group Intervention group Intervention versus
controlN = 300 N = 305
Mean (SEM) Mean (SEM) Mean difference (95% CI)
Healthcare costs 1021 (107) 1016 (92) −5 (-316;272)
Intervention 0 98 (2.4) 98 (NA)
Other 1021 (107) 918 (92) −104 (-414;173)
Participant costs 774 (69) 642 (45) −132 (-323;27)
Productivity losses 2918 (528) 2189 (340) −729 (-2008;285)
Total 4713 (626) 3847 (388) −866 (-2400;370)
NA, Not Applicable; SEM, Standard Error of the Mean.
a All costs are given in Euros adjusted to the year 2008.
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who received health brochures (Table 3). Almost 77%
of cost-effectiveness pairs were in the south-east quad-
rant, indicating likeliness for greater effectiveness at
lower costs. The CEAC showed the probability that
the intervention is cost-effective compared with health
brochures was 89% at a ceiling ratio of €0 per additional
QALY gained, 93% at €8000/QALY and 89% at €80,000/
QALY (Figure 2). This rise and subsequent fall in the prob-
ability of cost-effectiveness can be explained by looking at
the distribution of the cost and effect pairs in the CE-
plane. As the willingness to pay increases, the joint density
in the north-east quadrant (8.2%) is included as cost-
effectiveness before the joint density in the south-west
quadrant (12.9%) is excluded as no longer cost-effective
and the probability of cost-effectiveness drops [26].Table 3 Incremental cost-effectiveness ratios and distribution
plane




T2DM riskf Base case 300 305 −866 (-2372
Complete cases 117 105 −30 (-2171;1
Health care perspective 300 305 −5 (-316;27
CVD riskg Base case 300 305 −866 (-2372
Complete cases 116 104 −19 (-2253;1
Health care perspective 300 305 −5 (-316;27
QALY Base case 300 305 −866 (-2372
Complete cases 114 98 110 (-2004;1
Health care perspective 300 305 −5 (-316;27
ΔC = mean difference in total costs between the intervention group and control gr
is calculated as ΔC/ΔE. ICER, Incremental Cost-Effectiveness Ratio; NE, north-east; SE
CVD, Cardiovascular Disease; QALY, Quality Adjusted Life Years.
a The base case analysis and complete case analysis are based on the societal persp
missing data were multiply imputed. The complete cases analysis was restricted to part
b NE quadrant: the intervention is more effective and more costly than usual care.
c SE quadrant: the intervention is more effective and less costly than usual care.
d SW quadrant: the intervention is less effective and less costly than usual care.
e NW quadrant: the intervention is less effective and more costly than usual care.
f The at the age of 60 anticipated risk for developing T2DM in the following 9 years . gCost-effectiveness
The ICER of the 9-year risk for developing T2DM was
-1416. Over the two year period, a €1416 saving was
seen per 1% increase in risk for developing T2DM
among the intervention participants as compared to
those who received health brochures. The CE-plane
showed that the majority (86%) of the cost-effectiveness
pairs were located in the south-west quadrant, indicating
that the intervention is likely to be less expensive, but
also less effective than the alternative (Table 3). The CEAC
for T2DM-risk (not presented) showed that the probabil-
ity of cost-effectiveness at a ceiling ratio of €0 per one per-
cent risk modification was 90%. The CEAC dropped when
the amount that society is willing to pay or accept in-
creased. Beyond a ceiling ratio of approximately €1500 per
one percent risk change, the probability that healthof the joint cost-effect pairs in the cost-effectiveness
I) ΔE (95% CI) Distribution in cost-effectiveness
plane (%)
ICER NEb SEc SWd NWe
;370) 0.6 (-0.1;1.3) -1416 0.6 4.1 85.9 9.4
446) 0.7 (-0.4;1.7) -44 5.1 4.4 45.0 45.5
2) 0.6 (-0.1;1.3) −8 2.2 2.4 47.5 47.9
;370) −0.1 (-0.4;0.2) 6405 8.0 74.3 15.4 2.3
410) −0.03 (-0.34;0.29) 642 29.5 27.8 21.3 21.5
2) −0.1 (-0.4;0.2) 38 40.1 42.4 8.0 9.5
;370) 0.02 (-0.02;0.05) -50,273 8.2 76.8 12.9 2.1
611) 0.02 (-0.02;0.06) 4770 46.4 40.6 4.2 8.7
2) 0.02 (-0.02;0.05) −298 40.7 44.7 5.0 9.6
oup in Euros adjusted to the year 2008; ΔE = mean difference in outcome; ICER
, south-east; SW, south-west; NW, north-west; T2DM, Type 2 Diabetes Mellitus;
ective. In the base case analysis and the analysis from the health care perspective
icipants with complete data on costs and the particular clinical outcome.
The at the age of sixty anticipated risk of CVD mortality in the following 10 years.
Figure 2 Cost-effectiveness acceptability curve for Quality
Adjusted LifeYears (QALYs) gained.
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that the lifestyle intervention is cost-effective.
The ICER for the 10-risk of CVD mortality was 6405,
meaning that a 1% lower risk as a result of the interven-
tion is accompanied by a societal saving of €6405, com-
pared with health brochures (Table 3). Cost-effectiveness
pairs were mostly located (74%) in the south-east quad-
rant, indicative of higher effectiveness at lower cost
(Table 3). The probability of cost-effectiveness for CVD-
risk started at 90% at a ceiling ratio of €0 per one
percent risk modification and fell slightly to 80% at a
ceiling ratio of €10,000 per one percent risk modification
(CEAC not presented).
Sensitivity analyses
The sensitivity analyses in which costs and QALYs were
discounted, productivity losses were valued with the hu-
man capital method, the costs for sports were excluded
from the participant costs, missing number of follow-
up phone calls were multiply imputed, and 50 multiply
imputed data sets were created and analyzed, showed
similar results (Results shown in Additional file 3). The
sensitivity analysis in which only participants with com-
plete cost and effect data were included and the analysis
from the healthcare perspective, gave different results
(Table 3). In the complete case analysis the difference in
societal costs virtually disappeared, but the differences in
the clinical outcomes were similar to the main analysis.
The CEAC showed that for risk of T2DM that the prob-
ability of cost-effectiveness at a ceiling ratio of €0 was
50%. The CEAC for risk of CVD was around 50% at all
ceiling ratios. With regard to QALYs gained, the max-
imum probability of cost-utility compared with health
brochures was 45% at a ceiling ratio of €0/QALY, 75%
at €80,000/QALY and converged to 77% at €100,000/
QALY.
In the analysis from the healthcare perspective, the
cost difference between the groups reduced to €-5. Forall outcomes, the probability of cost-effectiveness was
around 50% at a ceiling ratio of €0. For T2DM the prob-
ability decreased as willingness to pay increased, whereas
for CVD it increased to nearly 70% at €10,000 per 1%
change. Probability of cost-utility was about 80% from
€25,000/QALY upwards, converging to 85% at the max-
imum willingness to pay.
Discussion
This study examined the cost-effectiveness of a primary
care intervention to prevent T2DM and CVD from a so-
cietal perspective, compared with provision of health
brochures. Small, statistically non-significant differences
in risk scores and QALYs gained were found between
the intervention and comparison group. The mean dif-
ference in costs was €-866 (95% CI -2372 to 370). The
probability of cost-effectiveness for health risk modifica-
tion was 90% at a ceiling ratio of €0. Increasing the ceil-
ing ratio resulted in a slight drop in the probability of
cost-effectiveness for risk of CVD, but severely for risk
of T2DM. The probability of cost-utility of the interven-
tion, compared with the brochures group, was around
90% at all ceiling ratios. The results were confirmed in
the sensitivity analyses, except in the complete case ana-
lysis. This showed that the intervention was not more
likely to be cost-effective for reducing health risks than
provision with health brochures. Furthermore, the prob-
ability of cost-utility reduced to a maximum of 77%.
Clinical outcomes
The results indicate that there were no statistically sig-
nificant differences between the intervention and control
group with regard to the clinical outcomes. Baseline
health utilities were already high, which implied that
there was little room for improvement in QALYs gained.
High baseline utilities and lack of improvement might
be related to the use of the EQ-5D-3L to measure health
status. This instrument is known for its ceiling effects in
relatively healthy populations. Other instruments, such
as the recently developed EQ-5D-5L might resolve this
problem, but this is still under research [27]. Lack of
differential effect on risk profile could be related to
the low attendance to the counseling sessions. On
average only 2.4 of the 6 available face-to-face counsel-
ing sessions had taken place, whereas the mean use of
the 3-monthly phone-calls was 2.3. These results
underscore the difficulties in translating efficacious
methods to interventions that are feasible and effective
in real-world settings.
Costs
Cost-differences were in favor of the intervention albeit
statistically not significant. Due to the skewed nature of
the cost data, the study may have been underpowered to
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ference in total costs was mostly explained by differences
in costs of productivity losses. To explore the effect of
outliers on these costs, a post-hoc analysis was done. In
this, the number of sick leave days was truncated at
30 days, as it is improbable that sick leave over 30 days
would have been influenced by the intervention. The
cost difference reduced to €-179 (95% CI -725 to 311).
However, a reduction in societal costs remained.
To our knowledge, no other studies of lifestyle inter-
ventions to prevent T2DM or CVD have found immedi-
ate cost reductions as a consequence of the program, in
the absence of health effects [4]. Some researchers have
suggested that health promotion programs have non-
health benefits that are currently not measured, such as
increased health literacy [28]. These benefits may have a
direct influence on health care use and sickness absen-
teeism [29]. The reduction in costs of personal expenses,
mainly consisting of sports costs, is puzzling. Because
the intervention participants were stimulated to be more
physically active, higher costs were expected. All in all,
the finding of possible cost savings in favor of the inter-
vention cannot be easily explained.
Cost-utility
The main aim of an economic evaluation is to decide
whether the treatment under scrutiny offers value for
money. Ceiling ratios for reductions in risk of CVD or
T2DM are not determined. The ceiling ratio for QALYs
gained in the Netherlands is also not established, but it
has been proposed to be set at €8000 for diseases with a
low burden and at €80,000 for diseases with a high bur-
den [30]. The immediate burden of disease of an ele-
vated risk for T2DM and CVD is unknown, but likely
lies at the lower end of the range. At a ceiling ratio of
€8,000 per QALY gained, the probability of cost-utility of
the intervention was 93%. At the higher end, probability
of cost-utility was 89% at a ceiling ratio of €80,000 per
QALY gained. The intervention therefore has a high
probability of cost-utility at all acceptable ceiling ratios.
However, there is methodological uncertainty regarding
this probability. The complete case analyses showed that
the probability that the true cost-utility ratio falls below
€80,000 is 75%. The analysis from the health care perspec-
tive also showed a lower probability of cost-effectiveness.
The post-hoc analysis in which the number of sick leave
days was truncated at 30 days, showed a maximum
probability of 70% at a ceiling ratio of €0. Thus, in these
sensitivity analyses, cost-utility results were less positive.
Furthermore, people generally demand larger compensa-
tions for losses compared with how much they are willing
to pay for gains (willingness to pay < willingness to
accept). If this aversion to loss is applicable to losses in
health, a lower probability of cost-utility would have beenfound [31]. Finally, as explained before, questions remain
about the cause of the cost-differences. In light of these
uncertainties, it is unsure if the possible benefits outweigh
the efforts involved in the implementation of this new
intervention.
Limitations and strengths
A limitation of the study is the amount of incomplete
cost data. Intervention costs were missing for 140/314
(45%) participants, mainly because the practice nurses
failed to report the number of phone sessions to the re-
search team. However, a more complete report may be
difficult to achieve in real-world settings. In addition,
36% of the self-reported data on health care utilization,
personal spending and sick leave was missing. This is
comparable to other RCTs in the Netherlands with a
follow-up of one year or longer [32,33]. Studies in the
Netherlands that need individual data on health care use
have to rely on self-report because it is not feasible to
collect these data from health insurers. Nevertheless,
methods to improve data-completeness in studies with
many self-reported cost-measurements should be de-
vised to increase the internal validity of these studies.
Over one-third of all cost data were imputed, using
multiple imputation techniques. In multiple imputation
it is assumed that unobserved data are (in part) depend-
ant on the observed data (e.g. available costs). However,
this assumption cannot be fully tested. Although me-
thodological studies show that multiple imputation is
preferred over complete case analyses and simple imput-
ation methods results from this study should be treated
with some caution.
The use of ‘projected’ risk scores for T2DM and CVD
was useful to accentuate absolute risk, but should not be
considered as current absolute risk. For both risk scores
and for each participant, age was extrapolated to 60 years
while all other variables in the risk scores (e.g. blood
pressure or cholesterol) were absolute scores. Thus, the
scores estimated the risk of participants as if they were
60 years old, but with current values.
Lastly, the time horizon of the study was too short to
observe the development of T2DM or CVDs, and to
measure their associated changes in QALYs achieved.
Decision modeling could be used to extend the time
horizon of the study. This would give more insight in
the longer term cost-effectiveness, and would increase
the comparability of the results to those from other
studies. Decision modeling also has the advantage that
the results of similar interventions could be included,
thereby broadening the evidence base [34]. This would
however have to be done in a separate study.
Strengths of the study include the relatively long-term
follow-up in terms of intermediate outcomes, the use of
multiple imputation to address the large amount of
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proach and the human capital approach to value product-
ivity losses, and the application of a randomized controlled
design in a real-world setting.
Conclusion
The lifestyle program offered by practice nurses to
adults at risk for T2DM and CVD was not more effect-
ive in reducing these risks than the provision of general
health brochures. However, the intervention appeared to
result in short-term cost savings. A high probability of
cost-utility was found at all ceiling ratios. Nevertheless,
due to methodological uncertainty no advice can be
given regarding the implementation of the intervention
in Dutch general practices.
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